Varini M, Tancini G, Mauri M, Di Pietro S
Tumori. 1979 Dec 31;65(6):703-12. doi: 10.1177/030089167906500606.
The medical records of 84 postmenopausal women treated with oral norethisterone acetate (NTA) for advanced breast cancer were retrospectively analyzed. Treatment was devoid of significant toxicity. Twenty-one patients were not evaluable for treatment response either because of insufficient data or inadequate treatment trial. Complete plus partial response was obtained in 21 (33.3%) of the 63 evaluable patients, with a median duration of 10 months. Disease stabilization was observed in 16 (25.4%) patients for a median duration of 5 months, while 26 patients (41.3%) showed progressive disease while on treatment. The best response was observed in women with dominant soft part disease and an age over 70 (CR+PR 48%). The literature on norethisterone acetate is reviewed and compared with present results. The role of progestational agents in the treatment of advanced mammary carcinoma is discussed.
对84例接受口服醋酸炔诺酮（NTA）治疗晚期乳腺癌的绝经后女性的病历进行了回顾性分析。治疗无明显毒性。21例患者因数据不足或治疗试验不充分而无法评估治疗反应。63例可评估患者中有21例（33.3%）获得完全缓解加部分缓解，中位持续时间为10个月。16例（25.4%）患者病情稳定，中位持续时间为5个月，而26例（41.3%）患者在治疗期间病情进展。在主要为软组织疾病且年龄超过70岁的女性中观察到最佳反应（完全缓解+部分缓解率为48%）。对醋酸炔诺酮的文献进行了综述并与当前结果进行了比较。讨论了孕激素类药物在晚期乳腺癌治疗中的作用。
